BPA for jelmyto
Ended Awarded Last action
- Contract number
- 36E79721A0008
- Awardee
-
Urogen Pharma Inc. UEI L3U3BFJL3Z81
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $2,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This single-award Blanket Purchase Agreement, valued at $2.5 million and awarded on March 1, 2021, by the National Acquisition Center to Urogen Pharma Inc., establishes a pre-negotiated procurement mechanism for JELMYTO (mitomycin) products through February 28, 2026. The contract operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with no set-aside designation and provides streamlined ordering capabilities for the U.S. Department of Veterans Affairs across multiple Veterans Integrated Service Networks. Urogen Pharma Inc., a pharmaceutical company headquartered in Princeton, New Jersey, supplies JELMYTO kits and JELMYTO mitomycin, a specialized pharmaceutical treatment for low-grade upper tract urothelial cancer affecting the urinary tract system. The BPA establishes standardized pricing and terms enabling the VA to issue delivery orders efficiently without conducting individual full and open competitions for each procurement action.
Under this indefinite delivery vehicle, the VA has the flexibility to issue multiple delivery orders to procure JELMYTO products as clinical demand dictates across its healthcare network, with historical delivery order values ranging from approximately $97,430 to $194,860. The BPA structure allows the Veterans Affairs system to support veteran healthcare services across geographically dispersed Veterans Integrated Service Networks by maintaining pre-negotiated terms and pricing for this critical oncological pharmaceutical. By establishing this ceiling value of $2.5 million through February 2026, the contract provides budgetary predictability while enabling responsive procurement of specialized cancer treatments required to support the VA's medical mission and veteran patient populations.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Show all 11
Quick answers
Who was awarded contract 36E79721A0008?
36E79721A0008 was awarded to Urogen Pharma Inc. by National Acquisition Center (Headquarters) on March 1, 2021.
How much is contract 36E79721A0008 worth?
36E79721A0008's own ceiling is $2,500,000.
Who can order from contract 36E79721A0008?
36E79721A0008 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79721A0008 under another contract?
Yes. 36E79721A0008 is a blanket purchase agreement under 36F79721D0068, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79721A0008 competed?
The extent of competition for 36E79721A0008 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV